Abstract

Background

Percutaneous mitral valve repair (PMVR) is an established therapy for mitral regurgitation (MR) in patients at high risk for surgical treatment. The aim of this study was to determine the impact of PMVR on left and right ventricular (LV, RV) and left and right atrial (LA, RA) remodelling according to the mechanism of MR and history of atrial fibrillation (AF).

Methods and results

Twenty-four patients (mean age 78.54 years ± 7.64 SD; 62.5% males) undergoing PMVR at our centre were prospectively enrolled. All the patients underwent echocardiography 1.6 ± 0.9 months before the procedure and after 5.7 ± 3.5 months; functional MR accounted for 54% of cases. Compared to baseline, a statistically significant improvement in LV end-diastolic diameter (LVEDD), LV indexed mass (ILVM), LV end-diastolic and end-systolic volumes (LVEDV, LVESV), indexed LA volume (iLAV) and morpho-functional RV parameters was recorded. LVEDD and LVEDV improved in primary MR cohort whereas in secondary MR a significant reduction in LVEDV and LVESV with a nonsignificant improvement in ejection fraction were found. (Table 1) LA positive remodelling was found in organic MR with a trend toward ameliorated function; in functional MR, with more dilated and dysfunctional LA, no significant improvement was found. (Table 1) Furthermore, a significant reduction of LA volumetry was detected only in patients without history of AF (AF baseline 51.4 mL/m2 IQR 45.6-62.5 mL/m2 f-u 48.9 mL/m2 IQR 42.9-59.2 mL/m2; p=0.101; no AF baseline 43.5 mL/m2 IQR 34.2-60.5 mL/m2 f-u 42.0 mL/m2 IQR 32.0-46.2 mL/m2; p=0.012). As regards right sections, the most relevant positive remodeling was obtained in patients with functional MR with a baseline poorer RV function and more severe RA and RV dilation. (Table 1)

Conclusion

At mid-term follow-up after PMVR, a positive cardiac remodeling is detected in atrial and ventricular chambers also involving the right sections. To deliver a tailored intervention, MR mechanism and history of AF should be considered in view of the impact on remodeling process.

Baseline, median [IQR]Follow-up, median [IQR]p val
PRIMARY MR (N=11)
LVEDD (mm)50.0 [49.0-59.0]46.0 [42.0–57.0].005
LVESD (mm)42.0 [37.0-49.0]40.0 [38.0–45.0].284
RWT0.32 [0.29-0.38]0.35 [0.31–0.38].424
iLVM (gr/m2)111.1 [95.1-142.9]79.2 [52.3–103.3].005
2D-iLVEDV (ml/m2)61.4 [45.4-77.7]48.9 [40.5-61.6].003
2D-iLVESV (ml/m2)25.2 [21.2-39.8]20.4 [14.75–30.8].182
2D-LVEF (%)59.1 [50.7-61.5]61.5 [50.0–63.9].477
LV-S’ (TDI) (cm/s)8.0 [7.5-9.5]8.0 [6.0–10.0].157
2D-iLAV (ml/m2)42.3 [34.2-51.7]36.3 [29.6–47.0].005
PALS (%)12.0 [4.0-17.0]21.0 [19.0–22.0].109
TR Vmax (m/s)3.0 [2.5-3.1]2.0 [1.8–2.5].005
EPSPAP (mmHg)40.0 [35.0-50.0]20.0 [15.0–25.0].003
Basal RVD (mm)35.0 [31.0-40.0]32.0 [29.0–37.0].058
Mid-cavity RVD (mm)27.0 [25.0-34.0]26.0 [23.0–31.0].010
Longitudinal RVD (mm)59.0 [52.0-68.0]53.0 [47.0–60.0].005
RA Area (cm2)18.0 [15.0-23.0]14.0 [13.0–16.0].035
FAC (%)37.0 [35.0-44.0]45.0 [43.0–47.0].016
TAPSE (mm)20.0 [17.0-24.0]20.0 [18.0-26.0].072
RV S’ (TDI) (cm/s)9.0 [8.0-13.7]9.0 [8.7–13.0].581
RV-FWLS (%)-21.0 [-15.1–-23.0]- 23.0 [-24.0 – -22.0].141
Baseline, median [IQR]Follow-up, median [IQR]p val
PRIMARY MR (N=11)
LVEDD (mm)50.0 [49.0-59.0]46.0 [42.0–57.0].005
LVESD (mm)42.0 [37.0-49.0]40.0 [38.0–45.0].284
RWT0.32 [0.29-0.38]0.35 [0.31–0.38].424
iLVM (gr/m2)111.1 [95.1-142.9]79.2 [52.3–103.3].005
2D-iLVEDV (ml/m2)61.4 [45.4-77.7]48.9 [40.5-61.6].003
2D-iLVESV (ml/m2)25.2 [21.2-39.8]20.4 [14.75–30.8].182
2D-LVEF (%)59.1 [50.7-61.5]61.5 [50.0–63.9].477
LV-S’ (TDI) (cm/s)8.0 [7.5-9.5]8.0 [6.0–10.0].157
2D-iLAV (ml/m2)42.3 [34.2-51.7]36.3 [29.6–47.0].005
PALS (%)12.0 [4.0-17.0]21.0 [19.0–22.0].109
TR Vmax (m/s)3.0 [2.5-3.1]2.0 [1.8–2.5].005
EPSPAP (mmHg)40.0 [35.0-50.0]20.0 [15.0–25.0].003
Basal RVD (mm)35.0 [31.0-40.0]32.0 [29.0–37.0].058
Mid-cavity RVD (mm)27.0 [25.0-34.0]26.0 [23.0–31.0].010
Longitudinal RVD (mm)59.0 [52.0-68.0]53.0 [47.0–60.0].005
RA Area (cm2)18.0 [15.0-23.0]14.0 [13.0–16.0].035
FAC (%)37.0 [35.0-44.0]45.0 [43.0–47.0].016
TAPSE (mm)20.0 [17.0-24.0]20.0 [18.0-26.0].072
RV S’ (TDI) (cm/s)9.0 [8.0-13.7]9.0 [8.7–13.0].581
RV-FWLS (%)-21.0 [-15.1–-23.0]- 23.0 [-24.0 – -22.0].141
Baseline, median [IQR]Follow-up, median [IQR]p val
PRIMARY MR (N=11)
LVEDD (mm)50.0 [49.0-59.0]46.0 [42.0–57.0].005
LVESD (mm)42.0 [37.0-49.0]40.0 [38.0–45.0].284
RWT0.32 [0.29-0.38]0.35 [0.31–0.38].424
iLVM (gr/m2)111.1 [95.1-142.9]79.2 [52.3–103.3].005
2D-iLVEDV (ml/m2)61.4 [45.4-77.7]48.9 [40.5-61.6].003
2D-iLVESV (ml/m2)25.2 [21.2-39.8]20.4 [14.75–30.8].182
2D-LVEF (%)59.1 [50.7-61.5]61.5 [50.0–63.9].477
LV-S’ (TDI) (cm/s)8.0 [7.5-9.5]8.0 [6.0–10.0].157
2D-iLAV (ml/m2)42.3 [34.2-51.7]36.3 [29.6–47.0].005
PALS (%)12.0 [4.0-17.0]21.0 [19.0–22.0].109
TR Vmax (m/s)3.0 [2.5-3.1]2.0 [1.8–2.5].005
EPSPAP (mmHg)40.0 [35.0-50.0]20.0 [15.0–25.0].003
Basal RVD (mm)35.0 [31.0-40.0]32.0 [29.0–37.0].058
Mid-cavity RVD (mm)27.0 [25.0-34.0]26.0 [23.0–31.0].010
Longitudinal RVD (mm)59.0 [52.0-68.0]53.0 [47.0–60.0].005
RA Area (cm2)18.0 [15.0-23.0]14.0 [13.0–16.0].035
FAC (%)37.0 [35.0-44.0]45.0 [43.0–47.0].016
TAPSE (mm)20.0 [17.0-24.0]20.0 [18.0-26.0].072
RV S’ (TDI) (cm/s)9.0 [8.0-13.7]9.0 [8.7–13.0].581
RV-FWLS (%)-21.0 [-15.1–-23.0]- 23.0 [-24.0 – -22.0].141
Baseline, median [IQR]Follow-up, median [IQR]p val
PRIMARY MR (N=11)
LVEDD (mm)50.0 [49.0-59.0]46.0 [42.0–57.0].005
LVESD (mm)42.0 [37.0-49.0]40.0 [38.0–45.0].284
RWT0.32 [0.29-0.38]0.35 [0.31–0.38].424
iLVM (gr/m2)111.1 [95.1-142.9]79.2 [52.3–103.3].005
2D-iLVEDV (ml/m2)61.4 [45.4-77.7]48.9 [40.5-61.6].003
2D-iLVESV (ml/m2)25.2 [21.2-39.8]20.4 [14.75–30.8].182
2D-LVEF (%)59.1 [50.7-61.5]61.5 [50.0–63.9].477
LV-S’ (TDI) (cm/s)8.0 [7.5-9.5]8.0 [6.0–10.0].157
2D-iLAV (ml/m2)42.3 [34.2-51.7]36.3 [29.6–47.0].005
PALS (%)12.0 [4.0-17.0]21.0 [19.0–22.0].109
TR Vmax (m/s)3.0 [2.5-3.1]2.0 [1.8–2.5].005
EPSPAP (mmHg)40.0 [35.0-50.0]20.0 [15.0–25.0].003
Basal RVD (mm)35.0 [31.0-40.0]32.0 [29.0–37.0].058
Mid-cavity RVD (mm)27.0 [25.0-34.0]26.0 [23.0–31.0].010
Longitudinal RVD (mm)59.0 [52.0-68.0]53.0 [47.0–60.0].005
RA Area (cm2)18.0 [15.0-23.0]14.0 [13.0–16.0].035
FAC (%)37.0 [35.0-44.0]45.0 [43.0–47.0].016
TAPSE (mm)20.0 [17.0-24.0]20.0 [18.0-26.0].072
RV S’ (TDI) (cm/s)9.0 [8.0-13.7]9.0 [8.7–13.0].581
RV-FWLS (%)-21.0 [-15.1–-23.0]- 23.0 [-24.0 – -22.0].141
Table 1

baseline and follow-up echocardiography assessment

Baseline, median [IQR]Follow-up, median [IQR]p val
secondARY MR (N=13)
LVEDD (mm)60.0 [53.0-65.0]60.0 [50.0–63.0].058
LVESD (mm)45.0 [40.5-52.0]47.0 [41.5–50.0].833
RWT0.31 [0.26-0.37]0.33 [0.25–0.38].347
iLVM (gr/m2)116.9 [96.2-136.4]100.8 [58.2–141.6].239
2D-iLVEDV (ml/m2)76.4 [60.5-94.9]59.4 [44.8–91.2].002
2D-iLVESV (ml/m2)50.2 [35.5-67.1]31.9 [23.1–53.9].004
2D-LVEF (%)42.4 [35.9-48.2]46.3 [38.5–49.6].433
LV-S’ (TDI) (cm/s)6.5 [5.3-8.0]8.0 [7.0–9.0].105
2D-iLAV (ml/m2)53.8 [45.2-62.6]50.7 [43.6–60.1].213
PALS (%)10.0 [5.0-17.0]6.8 [5.2–17.5].500
TR Vmax (m/s)2.9 [2.5-3.2]2.4 [2.0–2.7].056
EPSPAP (mmHg)42.5 [31.3-53.8]30.0 [20.0–35.0].005
Basal RVD (mm)39.0 [37.0-43.0]34.0 [32.0–38.5].004
Mid-cavity RVD (mm)30.0 [26.0-35.0]28.0 [21.5–29.5].016
Longitudinal RVD (mm)65.0 [60.5-71.0]60.0 [57.5–63.0].012
RA Area (cm2)21.0 [17.5-25.0]18.0 [15.5–22.5].040
FAC (%)34.0 [30.0-37.0]42.0 [34.0–48.5].009
TAPSE (mm)14.0 [13.0-14.0]17.0 [14.5–19.0].005
RV S’ (TDI) (cm/s)7.0 [6.0-10.8]9.5 [8.3–12.8].068
RV-FWLS (%)-15.0 [-9.9 – 19.8]- 19.5 [-16.0 – -22.5].021
Baseline, median [IQR]Follow-up, median [IQR]p val
secondARY MR (N=13)
LVEDD (mm)60.0 [53.0-65.0]60.0 [50.0–63.0].058
LVESD (mm)45.0 [40.5-52.0]47.0 [41.5–50.0].833
RWT0.31 [0.26-0.37]0.33 [0.25–0.38].347
iLVM (gr/m2)116.9 [96.2-136.4]100.8 [58.2–141.6].239
2D-iLVEDV (ml/m2)76.4 [60.5-94.9]59.4 [44.8–91.2].002
2D-iLVESV (ml/m2)50.2 [35.5-67.1]31.9 [23.1–53.9].004
2D-LVEF (%)42.4 [35.9-48.2]46.3 [38.5–49.6].433
LV-S’ (TDI) (cm/s)6.5 [5.3-8.0]8.0 [7.0–9.0].105
2D-iLAV (ml/m2)53.8 [45.2-62.6]50.7 [43.6–60.1].213
PALS (%)10.0 [5.0-17.0]6.8 [5.2–17.5].500
TR Vmax (m/s)2.9 [2.5-3.2]2.4 [2.0–2.7].056
EPSPAP (mmHg)42.5 [31.3-53.8]30.0 [20.0–35.0].005
Basal RVD (mm)39.0 [37.0-43.0]34.0 [32.0–38.5].004
Mid-cavity RVD (mm)30.0 [26.0-35.0]28.0 [21.5–29.5].016
Longitudinal RVD (mm)65.0 [60.5-71.0]60.0 [57.5–63.0].012
RA Area (cm2)21.0 [17.5-25.0]18.0 [15.5–22.5].040
FAC (%)34.0 [30.0-37.0]42.0 [34.0–48.5].009
TAPSE (mm)14.0 [13.0-14.0]17.0 [14.5–19.0].005
RV S’ (TDI) (cm/s)7.0 [6.0-10.8]9.5 [8.3–12.8].068
RV-FWLS (%)-15.0 [-9.9 – 19.8]- 19.5 [-16.0 – -22.5].021
Table 1

baseline and follow-up echocardiography assessment

Baseline, median [IQR]Follow-up, median [IQR]p val
secondARY MR (N=13)
LVEDD (mm)60.0 [53.0-65.0]60.0 [50.0–63.0].058
LVESD (mm)45.0 [40.5-52.0]47.0 [41.5–50.0].833
RWT0.31 [0.26-0.37]0.33 [0.25–0.38].347
iLVM (gr/m2)116.9 [96.2-136.4]100.8 [58.2–141.6].239
2D-iLVEDV (ml/m2)76.4 [60.5-94.9]59.4 [44.8–91.2].002
2D-iLVESV (ml/m2)50.2 [35.5-67.1]31.9 [23.1–53.9].004
2D-LVEF (%)42.4 [35.9-48.2]46.3 [38.5–49.6].433
LV-S’ (TDI) (cm/s)6.5 [5.3-8.0]8.0 [7.0–9.0].105
2D-iLAV (ml/m2)53.8 [45.2-62.6]50.7 [43.6–60.1].213
PALS (%)10.0 [5.0-17.0]6.8 [5.2–17.5].500
TR Vmax (m/s)2.9 [2.5-3.2]2.4 [2.0–2.7].056
EPSPAP (mmHg)42.5 [31.3-53.8]30.0 [20.0–35.0].005
Basal RVD (mm)39.0 [37.0-43.0]34.0 [32.0–38.5].004
Mid-cavity RVD (mm)30.0 [26.0-35.0]28.0 [21.5–29.5].016
Longitudinal RVD (mm)65.0 [60.5-71.0]60.0 [57.5–63.0].012
RA Area (cm2)21.0 [17.5-25.0]18.0 [15.5–22.5].040
FAC (%)34.0 [30.0-37.0]42.0 [34.0–48.5].009
TAPSE (mm)14.0 [13.0-14.0]17.0 [14.5–19.0].005
RV S’ (TDI) (cm/s)7.0 [6.0-10.8]9.5 [8.3–12.8].068
RV-FWLS (%)-15.0 [-9.9 – 19.8]- 19.5 [-16.0 – -22.5].021
Baseline, median [IQR]Follow-up, median [IQR]p val
secondARY MR (N=13)
LVEDD (mm)60.0 [53.0-65.0]60.0 [50.0–63.0].058
LVESD (mm)45.0 [40.5-52.0]47.0 [41.5–50.0].833
RWT0.31 [0.26-0.37]0.33 [0.25–0.38].347
iLVM (gr/m2)116.9 [96.2-136.4]100.8 [58.2–141.6].239
2D-iLVEDV (ml/m2)76.4 [60.5-94.9]59.4 [44.8–91.2].002
2D-iLVESV (ml/m2)50.2 [35.5-67.1]31.9 [23.1–53.9].004
2D-LVEF (%)42.4 [35.9-48.2]46.3 [38.5–49.6].433
LV-S’ (TDI) (cm/s)6.5 [5.3-8.0]8.0 [7.0–9.0].105
2D-iLAV (ml/m2)53.8 [45.2-62.6]50.7 [43.6–60.1].213
PALS (%)10.0 [5.0-17.0]6.8 [5.2–17.5].500
TR Vmax (m/s)2.9 [2.5-3.2]2.4 [2.0–2.7].056
EPSPAP (mmHg)42.5 [31.3-53.8]30.0 [20.0–35.0].005
Basal RVD (mm)39.0 [37.0-43.0]34.0 [32.0–38.5].004
Mid-cavity RVD (mm)30.0 [26.0-35.0]28.0 [21.5–29.5].016
Longitudinal RVD (mm)65.0 [60.5-71.0]60.0 [57.5–63.0].012
RA Area (cm2)21.0 [17.5-25.0]18.0 [15.5–22.5].040
FAC (%)34.0 [30.0-37.0]42.0 [34.0–48.5].009
TAPSE (mm)14.0 [13.0-14.0]17.0 [14.5–19.0].005
RV S’ (TDI) (cm/s)7.0 [6.0-10.8]9.5 [8.3–12.8].068
RV-FWLS (%)-15.0 [-9.9 – 19.8]- 19.5 [-16.0 – -22.5].021
This content is only available as a PDF.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)